Psoriasis Treatment Market Outlook 2031

  • The global psoriasis treatment market was valued at US$ 18.8 Bn in 2021
  • The global market is projected to advance at a CAGR of 8.7% from 2022 to 2031
  • The global psoriasis treatment market is anticipated to reach more than US$ 44 Bn by the end of 2031

Analysts’ Viewpoint on Psoriasis Treatment Market Scenario

The global psoriasis treatment market is expected to grow at a rapid pace during the forecast period. Increase in adoption of personalized medicines for improved patient outcomes has encouraged market players to focus on newer modalities and biosimilars post the COVID-19 impact. The trend of tailor-made medicine for effective management of the disease is expected to drive the global psoriasis treatment market. Led by rapid medical advancements, players are focusing on leveraging the popularity of biologics for product innovation to meet the increasing demand in developed regional markets. Manufacturers should also consider strategic collaborations and acquisitions to broaden their product portfolio and strengthen their presence in the global landscape.

psoriasis treatment market

Overview of Psoriasis Treatment Market

Rise in the psoriasis patient pool, approval of new biologic drugs for psoriasis, novel drug pipeline, and increase in access to psoriasis treatment in developing countries are anticipated to propel the global psoriasis treatment market.

Psoriasis is an autoimmune noncontagious disorder characterized by rapid and excessive proliferation of skin cells, resulting in patches of abnormal skin. Psoriasis is considered a long-term skin disorder characterized by plaques and thickened skin. Commonly affected areas on the body are around the scalp, knees, navel, and back of the forearms. Psoriasis is triggered by various factors, including environmental factors and genetic deformity. It is considered a non-curable disorder; however, a few treatments can ease the symptoms. Patients are likely to develop psoriatic arthritis at a faster rate. The number of patients with psoriatic arthritis has increased significantly over the last few years.

Request a sample to get extensive insights into the Psoriasis Treatment Market

Approval of New Biologics for Psoriasis Treatment to Benefit Healthcare Companies

Biologics have altered the landscape in the management of moderate to severe psoriasis by achieving improved skin clearance, control of symptoms, and quality of life for many affected people. Usage of biologics in psoriasis treatment has resulted in lucrative prospects for manufacturers in the market, as they compete for the development of new products to stay competitive in the market.

In April 2019, Novartis AG announced that the China Health Authority NMPA approved Cosentyx (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. This indicates promising potential of the plaque psoriasis treatment among patients.

Increase in Access to Psoriasis Treatment in Developing Economies to Propel Global Market

Psoriasis diagnosis and treatment alternatives are undergoing a sea change in emerging economies. Awareness about psoriasis is increasing in developing countries such as China and India due to various campaigns by governments and healthcare professionals. It has become easy to access physicians or dermatologists for treatment in developing countries.

In November 2018, Novartis Corporation Malaysia launched ‘Be Pso Positive’, a psoriasis campaign in Malaysia. The campaign was created by Edelman Malaysia in association with the Psoriasis Association of Malaysia and True Complexion. This is expected to increase the number of patients treated for psoriasis, thereby augmenting the psoriasis treatment market during the forecast period.

Request a custom report on Psoriasis Treatment Market

Superior Efficacy and Safety of Drugs to Boost Demand for Interleukin Inhibitors

In terms of drug class, the global psoriasis treatment market has been classified into TNF inhibitors, interleukin inhibitors, vitamin D analogs, corticosteroids, and others. The interleukin inhibitors segment is projected to dominate the global psoriasis treatment market during the forecast period. The segment's large market share can be attributed to the superior efficacy and safety of drugs in this class for the treatment of psoriasis. Rise in acceptance of this drug class is attributable to interleukin blockers, which are considered a viable option for patients who do not respond to other treatments.

Launch of New Drugs Administered through Injection to Augment Parenteral Treatment Options

Based on route of administration, the global psoriasis treatment market has been segregated into oral, parenteral, and topical. The parenteral segment accounted for the major share of the market in 2021. This trend is expected to continue during the forecast period. Growth of the segment can be ascribed to the increase in launch of new drugs to be administered through injection or intravenous (IV) infusion; and surge in the adoption of biologics for the treatment of psoriasis.

High Sales of Biologics in Developed Countries to Drive Revenue Flow in Retail Pharmacies

In terms of distribution channel, the global psoriasis treatment market has been divided into hospital pharmacies, retail pharmacies, and others. Retail pharmacies is projected to be a highly lucrative segment of the global market during the forecast period owing to higher sales of biologics in developed countries, including the U.S. and Canada.

Regional Outlook of Global Psoriasis Treatment Market

North America dominated the global psoriasis treatment market in 2021 owing to the increase in incidence of psoriasis and favorable reimbursement policies in the region. Higher cost of biologics in North America than that in other regions is also likely to make it a primary market for players offering psoriasis treatment products. Additionally, robust product pipeline of key players is projected to boost the market in the region.

The psoriasis treatment market in Asia Pacific is anticipated to grow at a higher CAGR than that in North America during the forecast period due to the increase in awareness about psoriasis in developing countries of the region. Rise in diagnosis and management of psoriasis in healthcare systems & clinics in emerging economies is boosting the market in Asia Pacific. Furthermore, growth in usage of biologics in China and Japan is expected to augment the market in the region.

Recent advancements in psoriasis treatment is being witnessed in terms of new product approvals. In August 2021, Novartis secured a new approval for Cosentyx (secukinumab) for the treatment of pediatric moderate to severe plaque psoriasis in China.

The market in Latin America and Middle East & Africa is likely to grow at a considerable CAGR during the forecast period owing to the increase in psoriasis patient pool and focus of manufacturers on the development of novel therapeutics in these regions.

Analysis of Key Players in Psoriasis Treatment Market

Manufacturers of psoriasis drugs are focusing on the launch of new products and are promoting their brands in order to increase market share. Psoriasis drug manufacturers emphasize on new marketing strategies to boost product penetration. Companies consider product approval and launch as a critical component of their growth strategy. They also concentrate on developing a value chain for major regional markets, as well as developing new psoriasis drugs and long-term solutions. Key players operating in the global psoriasis treatment market include Amgen, Inc., Eli Lilly and Company, Novartis AG, Merck & Co., Inc., Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, AbbVie, Inc., LEO Pharma A/S, and Biogen, Inc.

Key Developments in Global Psoriasis Treatment Market

  • In February 2021, Amgen announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis
  • In April 2021, AbbVie announced that it had submitted applications seeking approval for SKYRIZI (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA), and for SKYRIZI (risankizumab, 150 mg) to the European Medicines Agency (EMA), for the treatment of adults with active psoriatic arthritis

Each of these players has been profiled in the psoriasis treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Psoriasis Treatment Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 18.8 Bn

Market Forecast Value in 2031

More than US$ 44 Bn

Growth Rate (CAGR)

8.7%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Drug Class
    • TNF Inhibitors
    • Interleukin Inhibitors
    • Vitamin D Analogs
    • Corticosteroids
    • Others
  • Route of Administration
    • Oral
    • Parenteral
    • Topical
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amgen, Inc.
  • Eli Lilly and Company
  • Novartis AG
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Pfizer, Inc.
  • AstraZeneca plc
  • AbbVie, Inc.
  • LEO Pharma A/S
  • Biogen, Inc.

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

The global psoriasis treatment market was valued at US$ 18.8 Bn in 2021.

The global market is projected to reach more than US$ 44 Bn by 2031.

The global psoriasis treatment market greew at a CAGR of 10.4% from 2017 to 2021.

The global psoriasis treatment market is anticipated to expand at a CAGR of 8.7% from 2022 to 2031.

Increase in number of psoriasis patients is augmenting the global psoriasis treatment market.

North America is expected to account for major share of the global psoriasis treatment market during the forecast period.

Prominent players in the global psoriasis treatment market include Amgen, Inc., Eli Lilly and Company, Novartis AG, Merck & Co., Inc., Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, AbbVie, Inc., LEO Pharma A/S, and Biogen, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Psoriasis Treatment Market

4. Market Overview

    4.1. Introduction

        4.1.1. Drug Class Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Psoriasis Treatment Market Analysis and Forecast, 2017–2031

        4.4.1. Market Revenue Projections (US$ Mn)

        4.4.2. Market Volume/Unit Shipments Projections

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Regulatory Scenario by Region/Key Country

    5.2. Pipeline Analysis

    5.3. Key Mergers & Acquisitions

    5.4. COVID-19 Impact Analysis

6. Global Psoriasis Treatment Market Analysis and Forecast, by Drug Class

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Drug Class, 2017–2031

        6.3.1. TNF Inhibitors

        6.3.2. Interleukin Inhibitors

        6.3.3. Vitamin D Analogs

        6.3.4. Corticosteroids

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug Class

7. Global Psoriasis Treatment Market Analysis and Forecast, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Route of Administration, 2017–2031

        7.3.1. Oral

        7.3.2. Parenteral

        7.3.3. Topical

    7.4. Market Attractiveness Analysis, by Route of Administration

8. Global Psoriasis Treatment Market Analysis and Forecast, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Distribution Channel, 2017–2031

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Others

    8.4. Market Attractiveness Analysis, by Distribution Channel

9. Global Psoriasis Treatment Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Psoriasis Treatment Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Drug Class, 2017–2031

        10.2.1. TNF Inhibitors

        10.2.2. Interleukin Inhibitors

        10.2.3. Vitamin D Analogs

        10.2.4. Corticosteroids

        10.2.5. Others

    10.3. Market Value Forecast, by Route of Administration, 2017–2031

        10.3.1. Oral

        10.3.2. Parenteral

        10.3.3. Topical

    10.4. Market Value Forecast, by Distribution Channel, 2017–2031

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Others

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Drug Class

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country

11. Europe Psoriasis Treatment Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Drug Class, 2017–2031

        11.2.1. TNF Inhibitors

        11.2.2. Interleukin Inhibitors

        11.2.3. Vitamin D Analogs

        11.2.4. Corticosteroids

        11.2.5. Others

    11.3. Market Value Forecast, by Route of Administration, 2017–2031

        11.3.1. Oral

        11.3.2. Parenteral

        11.3.3. Topical

    11.4. Market Value Forecast, by Distribution Channel, 2017–2031

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Others

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Drug Class

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Psoriasis Treatment Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Class, 2017–2031

        12.2.1. TNF Inhibitors

        12.2.2. Interleukin Inhibitors

        12.2.3. Vitamin D Analogs

        12.2.4. Corticosteroids

        12.2.5. Others

    12.3. Market Value Forecast, by Route of Administration, 2017–2031

        12.3.1. Oral

        12.3.2. Parenteral

        12.3.3. Topical

    12.4. Market Value Forecast, by Distribution Channel, 2017–2031

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Others

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Drug Class

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Psoriasis Treatment Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Class, 2017–2031

        13.2.1. TNF Inhibitors

        13.2.2. Interleukin Inhibitors

        13.2.3. Vitamin D Analogs

        13.2.4. Corticosteroids

        13.2.5. Others

    13.3. Market Value Forecast, by Route of Administration, 2017–2031

        13.3.1. Oral

        13.3.2. Parenteral

        13.3.3. Topical

    13.4. Market Value Forecast, by Distribution Channel, 2017–2031

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Others

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Drug Class

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Psoriasis Treatment Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Class, 2017–2031

        14.2.1. TNF Inhibitors

        14.2.2. Interleukin Inhibitors

        14.2.3. Vitamin D Analogs

        14.2.4. Corticosteroids

        14.2.5. Others

    14.3. Market Value Forecast, by Route of Administration, 2017–2031

        14.3.1. Oral

        14.3.2. Parenteral

        14.3.3. Topical

    14.4. Market Value Forecast, by Distribution Channel, 2017–2031

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Others

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Drug Class

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. Amgen, Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Product Portfolio

            15.3.1.3. SWOT Analysis

            15.3.1.4. Strategic Overview

        15.3.2. AstraZeneca plc

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Product Portfolio

            15.3.2.3. SWOT Analysis

            15.3.2.4. Strategic Overview

        15.3.3. AbbVie, Inc.

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Product Portfolio

            15.3.3.3. SWOT Analysis

            15.3.3.4. Strategic Overview

        15.3.4. Eli Lilly and Company

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Product Portfolio

            15.3.4.3. SWOT Analysis

            15.3.4.4. Strategic Overview

        15.3.5. Johnson & Johnson

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Product Portfolio

            15.3.5.3. SWOT Analysis

            15.3.5.4. Strategic Overview

        15.3.6. Biogen, Inc.

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Product Portfolio

            15.3.6.3. SWOT Analysis

            15.3.6.4. Strategic Overview

        15.3.7. Novartis AG

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Product Portfolio

            15.3.7.3. SWOT Analysis

            15.3.7.4. Strategic Overview

        15.3.8. Merck & Co., Inc.

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Product Portfolio

            15.3.8.3. SWOT Analysis

            15.3.8.4. Strategic Overview

        15.3.9. Pfizer, Inc.

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Product Portfolio

            15.3.9.3. SWOT Analysis

            15.3.9.4. Strategic Overview

        15.3.10. LEO Pharma A/S

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Product Portfolio

            15.3.10.3. SWOT Analysis

            15.3.10.4. Strategic Overview

        15.3.11. Other Players

List of Table

Table 01: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 03: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 04: Global Psoriasis Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 06: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 07: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 08: North America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 10: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 11: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 12: Europe Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 14: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 15: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 18: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 19: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 20: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Drug Class, 2017–2031

Table 22: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 23: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 24: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

List of Figures

Figure 01: Global Psoriasis Treatment Market Snapshot, 2021

Figure 02: Global Psoriasis Treatment Market Size (US$ Mn) Forecast, 2017–2031

Figure 04: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021

Figure 06: Global Psoriasis Treatment Market Value Share, by Region, 2021

Figure 03: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021

Figure 05: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021

Figure 07: Regulatory Approval Process - U.S.

Figure 08: Regulatory Approval Process - Europe

Figure 09: Regulatory Approval Process - Japan

Figure 10: Global Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 11: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by TNF Inhibitors, 2017–2031

Figure 12: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Interleukin Inhibitors, 2017–2031

Figure 13: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Vitamin D Analogs, 2017–2031

Figure 14: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroids, 2017–2031

Figure 15: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 16: Global Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 17: Global Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031

Figure 18: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2017–2031

Figure 19: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral, 2017–2031

Figure 20: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Topical, 2017–2031

Figure 21: Global Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 22: Global Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 23: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2031

Figure 24: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2031

Figure 25: Global Psoriasis Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017–2031

Figure 26: Global Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 27: Global Psoriasis Treatment Market Value Share, by Region, 2021 and 2031

Figure 28: Global Psoriasis Treatment Market Attractiveness Analysis, by Region, 2022–2031

Figure 29: North America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 30: North America Psoriasis Treatment Market Attractiveness Analysis, by Country, 2022–2031

Figure 31: North America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 32: North America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031

Figure 33: North America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 34: North America Psoriasis Treatment Market Value Share Analysis, by Country, 2021 and 2031

Figure 35: North America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 36: North America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 37: North America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 38: Europe Psoriasis Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2031

Figure 39: Europe Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 40: Europe Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 41: Europe Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 42: Europe Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031

Figure 43: Europe Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 44: Europe Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 45: Europe Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 46: Europe Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031

Figure 47: Asia Pacific Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 48: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 49: Asia Pacific Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 50: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 51: Asia Pacific Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031

Figure 52: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 53: Asia Pacific Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 54: Asia Pacific Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 55: Asia Pacific Psoriasis Treatment Market Value Share, by Country/Sub-region, 2021 and 2031

Figure 56: Latin America Psoriasis Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031

Figure 57: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 58: Latin America Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 59: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 60: Latin America Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031

Figure 61: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 62: Latin America Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 63: Latin America Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 64: Latin America Psoriasis Treatment Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

Figure 65: Middle East & Africa Psoriasis Treatment Market Value (US$ Mn) Forecast, 2017–2031

Figure 66: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

Figure 67: Middle East & Africa Psoriasis Treatment Market Value Share, by Drug Class, 2021 and 2031

Figure 68: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Drug Class, 2022–2031

Figure 69: Middle East & Africa Psoriasis Treatment Market Value Share, by Route of Administration, 2021 and 2031

Figure 70: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Route of Administration, 2022–2031

Figure 71: Middle East & Africa Psoriasis Treatment Market Value Share, by Distribution Channel, 2021 and 2031

Figure 72: Middle East & Africa Psoriasis Treatment Market Attractiveness Analysis, by Distribution Channel, 2022–2031

Figure 73: Middle East & Africa Market Value Share, by Country/Sub-region, 2021 and 2031

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Psoriasis Treatment Market